Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This trial is designed to assess the safety, tolerability, pharmacokinetics and viral
kinetics after multiple infusions of bavituximab in patients co-infected with HCV and HIV.